retatrutide clinical data retatrutide ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial Retatrutide vs Tirzepatide (2026): Differences

How PlexusDx Supports a More Personalized Approach PlexusDx partners with patients and providers to move beyond standardized telehealth protocols

Each may support metabolism, red blood cell formation and energy production

And there are even more effective treatments on the horizon (e.g., patients losing 2530% of their body weight, experiencing more significant improvements in underlying biomarkers like A1C, LDL, BP, and benefitting from improvements in their quality of life)

This translates into $126 billion in sales by 2029, a 2023-2029 sales CAGR of 30%

Excess body weight places significant pressure on spinal discs and joints